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Abstract
Introduction: Fibromyalgia is a chronic rheumatic disease producing widespread pain, associated to a major comorbidity -irritable bowel 
syndrome. Low FODMAPS diet (low fermentable oligo-di-mono-saccharides and polyols diet) has been effective in controlling irritable bowel 
syndrome symptoms. Overweight is an aggravating factor for fi bromyalgia. We studied effects of low fermentable oligo-di-mono-saccharides and 
polyols diets on fi bromyalgia symptoms and weight status.
Methods: A longitudinal study was performed on 38 fi bromyalgia patients using a four-week, repeated assessment as follow: M1 = fi rst 
assessments/presentation of individual low fermentable oligo-di-mono-saccharides and polyols diet; M2 = second assessments/reintro-
duction of FODMAPs; M3 = fi nal assessments/nutritional counselling. The assessment instruments applied were: Fibromyalgia Survey 
Questionnaire (FSQ); Severity Score System (IBS-SSS); visual analogic scale (VAS). Body mass-index/composition and waist circumference 
(WC) were also measured. Daily macro-micronutrients and FODMAP intake were quantifi ed at each moment of the study. 
Results: The studied cohort was 37% overweight, 34% obese (average body mass-index 27.4 ± 4.6; excess fat mass 39.4 ± 7%). Weight, body 
mass-index and waist circumference decreased signifi cantly (p < 0.01) with low fermentable oligo-di-mono-saccharides and polyols diet, 
but no signifi cant effect on body composition was observed. All fi bromyalgia symptoms, including somatic pain, declined signifi cantly post-LFD 
(p < 0.01); as well for severity of fi bromyalgia [Fibromyalgia survey questionnaire: M1 = 21.8; M2 = 16.9; M3 = 17.0 (p < 0.01)]. The intake 
of essential nutrients (fi ber, calcium, magnesium and vitamin D) showed no signifi cant difference. The signifi cant reduction in FODMAP intake (M1 
= 24.4 g; M2 = 2.6g; p < 0.01) refl ected the “Diet adherence” (85%). “Satisfaction with improvement of symptoms” (76%), showed correlating 
with “diet adherence” (r = 0.65; p < 0.01).
Conclusions: Results are highly encouraging, showing low fermentable oligo-di-mono-saccharides and polyols diets as a nutritionally balanced 
approach, contributing to weight loss and reducing the severity of FM fi bromyalgia symptoms. 
Resumen
Introducción: la fi bromialgia es una enfermedad reumática crónica, que tiene unas importantes comorbilidades -síndrome del intestino irritable 
(SII). La dieta baja en FODMAPs (low fermentable oligo-di-mono-saccharides and polyols diet) ha sido efi caz en el tratamiento del síndrome 
del intestino irritable. El sobrepeso es un factor agravante. Se estudiaron los efectos nutricionales del FODMAPs en la fi bromialgia.
Métodos: estudio longitudinal en 38 pacientes con fi bromialgia en el que se utilizó una evaluación repetida, durante cuatro semanas, de lo 
siguiente: Moment 1 (M1) = primeras evaluaciones/presentación de FODMAPs; M2 = segundas evaluaciones/reintroducción de FODMAPs; M3 
= evaluaciones fi nales/asesoramiento nutricional. Instrumentos de evaluación: Fibromialgia Survey Questionnaire; síndrome del intestino irritable 
(IBS-SSS), escala visual analógica (EVA) y parámetros antropométricos. Cuantifi cación en todo momento de las ingestas diarias de macro/micro 
nutrientes y FODMAPs.
Resultados: el estudio de cohorte mostró 37% de sobrepeso y 34% obesidad; índice de masa corporal = 27,4 ± 4,6; masa grasa = 39,4 ± 7%. 
El peso y la circunferencia de la cintura disminuyeron signifi cativamente con FODMAPs, pero no cambió la composición corporal. Los síntomas 
y la severidad de la fi bromialgia (FSQ: M1 = 21,8; M2 = 16,9; M3 = 17,0) se redujeron signifi cativamente después de FODMPAs (p < 0,01). 
No fueron observadas diferencias signifi cativas en el consumo de nutrientes esenciales, especialmente la fi bra, calcio, magnesio y vitamina 
D. El “seguimiento de la dieta” fue del 85% con reducción signifi cativa de la ingesta de FODMAPs (p < 0,01: M1 = 24,4 g; M2 = 2,6 g). “La 
satisfacción con la mejora de los síntomas” (76%) se correlacionó con el “seguimiento de la dieta” (r = 0,65; p < 0,01).
Conclusiones: los resultados son muy alentadores, mostrando FODMAPs como un enfoque equilibrado nutricionalmente, que contribuyó a la 
pérdida de peso y redujo signifi cativamente la severidad de la FM.
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INTRODUCTION
Fibromyalgia (FM) is a functional, diffuse, widespread pain-syn-
drome classified and recognized by the World Health Organization 
as a rheumatic pathology with unknown aetiology and currently 
with no specific effective pharmacotherapy (1). Globally, FM is the 
third most frequent rheumatic disease, presenting a prevalence 
of 3.7%, in Portugal (2) and an average age of affliction of 59 
years old (3). 
FM is a chronic disease having strong impact on the quality of 
life and, similarly to the majority of chronic diseases, there is a 
substantial relationship between nutrition, health and well-being 
(4). Current guidelines consistently recommend a multidisciplinary 
approach for treating FM (5), wherein nutrition could play a key role. 
In addition, obesity is a common factor in patients presenting FM 
(6). However, it is difficult to determine if obesity associated with 
FM is a consequence of inactivity imposed by pain, mental state, 
medication or other factors, or inversely, if obesity directly contrib-
utes to FM as an physiopathological aspect. Several studies found 
that being overweight can affect symptoms of FM (6). Arranz et al. 
showed a specific body composition in FM patients (high fat mass 
and low fat free mass) and found that BMI and body composition 
were correlated with quality of life and symptoms in FM patients (7).
Fava et al. described an increased metabolic risk, with insulin 
resistance, in FM patients probably due to a relationship between 
BMI and C-reactive protein, reflecting a micro-inflammation envi-
ronment, especially in obese FM patients (8). In another study, 
Alcocer-Gómez et al. showed, in vitro, that restricting caloric con-
tent to patients fibroblasts, resulted in improved AMP phosphor-
ylation, mitochondrial function and stress response, suggesting 
diet might have an in vivo role in FM treatment (9).
Food sensitivities are also frequently reported by FM patients, 
indicating a potential dietary link to central sensitization (10). A 
food awareness survey showed that 30% of FM patients attempt-
ed to control symptoms by restricting particular foods (11). Slim 
et al. proposed dietary interventions for FM treatment using a 
restricted gluten, lactose or FODMAPs diet; recently, published the 
results of the pilot trial comparing a gluten free diet (GFD) with a 
hypocaloric diet (HCD) in FM patients with gluten sensitivity symp-
toms (NCGS) (12,13); showed no significant difference between 
the two interventions but with similar benefits in the outcomes. 
Despite its specificity, GFD wasn’t superior to HCD, including the 
effects in NCGS (14).This study is in accordance with the opinion 
of other authors as Biesiekiersk: gluten restriction has no effect 
in patients with non-celiac gluten sensitivity (NCGS), and suggest-
ed that “wheat FODMAP” could be the trigger of FM symptoms, 
instead of gluten (15).
As a whole, the above results suggest that diet can have a 
potential therapeutic role in the balance of FM syndrome. One 
possible dietary approach could be to restrict FODMAPs (Fer-
mentable Oligo-Di-Mono-saccharides And Polyols) as part of a 
multidisciplinary treatment of FM (16). FODMAPs are composed 
by, poorly absorbed, short-chain carbohydrates, including excess 
free fructose, lactose, polyols, fructo-oligosaccharides, and galac-
to-oligosaccharides (17). A low FODMAP diet (LFD) was already 
found to alleviate GI disorders and symptoms of IBS (16,18) and 
by comparison, as about 70% of FM patients report IBS symp-
toms (19), we hypothesized that LFDs may have some therapeutic 
benefit on FM symptoms. 
It’s based in the evidence that, patients with IBS could present 
extraintestinal symptoms (2/3 prevalence of rheumatic disease). 
Symptoms of IBS usually overlap in 70% of FM patients and 60% 
inversely. Clinically FM does not differ whether or not it has asso-
ciated IBS symptoms (19,20,22).
Literature suggests a possible common cause, responsible 
by both conditions. Common characteristics between IBS and 
FM: both are characterized by functional pain, not explained by 
biochemical or structural abnormalities, with predominance in 
females, associating with life-stressing and complain of sleep 
disturbances and fatigue. Therapeutic response to the same phar-
macotherapy and psychotherapy is described. 
Some authors consider contradictory the association between 
IBS and FM relating it with anti-inflammatory drugs or possible 
diagnosis of celiac disease in a history of FM.
To date weren’t found studies showing the impact of results of 
LFDs on FM symptoms. This study was a pilot clinical trial on LFDs 
impact on FM symptoms and nutritional status of participants. 
Also, was included the objective of demonstrate the nutritional 
balance of the LFDs.
MATERIALS AND METHODS
PARTICIPANTS
A longitudinal study, involving introduction of LFDs to partic-
ipants suffering from FM. All participants were referred from a 
qualified rheumatologist having a confirmed diagnosis of FM, 
according to American College of Rheumatology criteria, 2011 
(22). The trial was conducted between January and May 2015, 
based on a four-week, repeated assessment model. 
All patients signed an Informed consent agreement (2013 
Declaration of Helsinki) to participate in the trial. The research 
project was approved by the Ethics Committee, Medical Aca-
demic Centre of Lisbon.
Inclusion criteria for participants were: 18-70 years old; 
diagnosed with FM at least one year; having received FM ther-
apy for at least 3 months prior to the study enrollment; and 
having already excluded referrals on a restricted FODMAP diet, 
or having comorbidities requiring specific nutritional therapy. 
Exclusion criteria included the co-morbidities requiring specific 
nutritional approaches such as renal insufficiency, diabetes, 
celiac disease. Participants with intercurrences as Influenza 
and respiratory infections were excluded.
STUDY PROTOCOL
The study consisted in three different assessments “Moments” 
of four weeks each, at repeated intervals, completing eight weeks 
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of intervention. A physician and a registered dietician were present 
at all assessments and available throughout the trial.
At the beginning (Moment 0) participants were introduced to the 
purpose and protocol of the trial. They signed informed consent 
agreements and received a booklet containing instructions and 
recipes for preparing food, as well as tables with the food rich in 
FODMAPs and a record-keeping section for cataloguing foods and 
food amounts consumed over a 72 h period. 
The recommended diet in Moment 1 (M1) was elaborated 
reducing lactose, replacing it by lactose free products and dairy 
alternative drinks; reducing excess of fructose replacing apple, 
mango, peaches, pear, watermelon, honey, sweeteners as fruc-
tose, HFCS, by banana, blueberry, grape, melon, orange, straw-
berry; reducing fructans rich foods as wheat, rye, onion, garlic 
replacing them by corn, spelt, rice, oat, gluten free products and 
garlic-infused oil; reducing galactans rich foods as cabbage, 
chickpeas, beans, lentils replacing them by vegetables as carrot, 
celery, green beans, lettuce, pumpkin, potato, tomato; reducing 
polyols rich foods as apricots, cherries, nectarine, plums, cauli-
flower, sorbitol xilitol replacing them by fruits as grapefruit, kiwi-
fruit, lemon, lime, passionfruit.
Total FODMAP intake [collective amounts of lactose, fructans, 
galactans, free fructose and polyols (g/day)], energy (kcal/day), 
and macronutrients/micronutrients consumed by the participants 
were quantified for each monitoring period (Moment). Participants 
reported individual food intake based on standardized dish, cup, 
and spoon measurements. The estimated dietary intake was cal-
culated from these measurements. Quantities were based upon 
published amounts of FODMAPs and respective food composition 
tables (23,24). 
At Moment 1 (M1), a clinical/dietary anamnesis was performed 
to obtain biographic and demographic data, comorbidities, medi-
cation requirements, food allergies or intolerances. Anthropomet-
ric assessments [weight, body mass index (BMI) and waist circum-
ference (WC)] were performed. OMRON equipment (HBF-511B-E/
HBF-511T-E) was used to evaluate fat mass and fat free mass. 
All participants completed the questionnaires, which included: 
–  Fibromyalgia Severity Questionnaire (FSQ), validated accord-
ing to the new ACR criteria, using a “widespread pain index” 
(19 points) and a “severity score index” (12 points), wherein 
combined scores ≥ 13 (0-31) indicate positive criteria of 
FM (22). 
–  Irritable Bowel Syndrome-Symptom Severity Scale (IBS-
SSS)- uses a five visual analogue scale to quantify abdom-
inal pain, abdominal distension, intestinal transit and the 
interference of IBS in daily life (0-500), score-ranked as 
“mild disease” (75-175), “moderate disease” (175-300) 
and “serious illness” (> 300) (25).
–  Clinical Outcomes in Routine Evaluation-Outcome Measure 
(Core-OM) assessed the mental state and is scored 0-4 (26).
–  Visual Analogic System (VAS) was applied for calibrating 
individual symptoms. 
All assessment tolls are validated in English language; FSQ, 
Core-OM and VAS in Portuguese language. Each participant 
received a personal dietary plan (DP) for restricting foods rich in 
accordance to FODMAPs. The delivery of the DP was accompa-
nied with accurate instructions and a request for utmost cooper-
ation and compliance. Investigators and participants were totally 
available to communicate by phone or email in a regular basis. 
At Moment 2 (M2) clinical/nutritional data were collected and 
all questionnaires were filled in, as at Moment 1. In addition, 
participants completed a questionnaire concerning their satis-
faction and adherence to their diet. This questionnaire included 
questions about overall satisfaction with the study and specific 
satisfaction with symptoms improvement. Instructions were then 
given for gradual reintroduction of FODMAPs into their assigned 
dietary plan (DP). Was chosen a food, representing each FODMAP 
group, to be reintroduce, increasing the doses along 3 days with 
a three-day washout period. 
Moment 3 (M3) was dedicated to determine any effects result-
ing from reintroduction of FODMAPs. Clinical and nutritional eval-
uations were made and assessment questionnaires applied in 
Moments 1 and 2 were filled in. Lastly, final dietary advice was 
provided to participants, encouraging them to maintain a balanced 
diet adjusted to body weight, and to exclude FODMAPs individually 
identified as being triggers of any negative symptoms.
STATISTICAL ANALYSIS
The Kolmogorov-Smirnov normality test, with Lillifors correc-
tion, was initially used to assess data normality. Changes in val-
ues between Moments were tested using analyses of variance 
(ANOVA) for repeated measures or the non-parametric Friedman 
test, if data were evaluated as not normally distributed. For the 
correlations analyses Pearson test or Spearman test were used. 
All analyses were performed using SPSS (version 22.0; SPSS, 
Inc., Chicago, IL, USA), and the significance level was set at p ≤ 
0.01 for all tests.
RESULTS 
NUTRITIONAL STATUS OF PARTICIPANTS 
The cohort consisted of 38 female participants with an average 
age of 51 years old, and 10 years of diagnosed FM. Thirty-one 
participants (82%) completed all trial phases. Four types of comor-
bidities were identified among participants, including gastrointes-
tinal (GI) disorders as diarrhoea, constipation, gastritis, being most 
common (n = 33; 88%), osteoarthritic disorders (n = 28; 74%), 
immuno-allergies (n = 23; 60%) and endocrine disorders, such 
as thyroid dysfunction (n = 7; 18%). 60% of participants (n = 23) 
reported some form of food intolerance and 11% (n = 4) were 
allergic to certain foods (documented).
At the outset of the trial, the cohort presented a mean weight 
of 69 ± 12 kg, BMI of 27.4 ± 4.6 kg/m2, body composition with 
excess fat mass (39.4 ± 7%) and a fat free mass in the lower 
limit (25.5 ± 3%), with an average WC of 84 ± 9 cm. Accordingly, 
a total of 27/38 (71%) of participants had excess of weight, 14 
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(37%) of them classified as obese. Only 11/38 (29%) were normal 
weight (Table I).
There was a significant decline in certain anthropomorphic 
indices among participants between M1 and M2 (restricting 
FODMAPs). There were significant reductions in mean Weight (> 
-1 kg; p < 0.01), BMI (-0.4 kg/m2; p < 0.01) and WC (-2.5 cm; 
p < 0.01). However, no significant changes occurred with body 
composition (fat mass and fat free mass). The assessment made 
after reintroduction of FODMAPs, showed no significant changes 
(between M2 and M3) in all the parameters studied (Table II). 
Reduction in WC occurred simultaneously with a large reduction in 
abdominal distension with significant decline (VAS bloating score: 
M1 = 6.9, M2 = 2.8; M3 = 3.8; p < 0.01) (Table III). 
DIETS 
During all assessment moments, diet was characterized accord-
ing to macro- and micronutrients including FODMAPs intakes, 
with the objective to demonstrate the nutritional balance of the 
LFDs. Average FODMAP intake declined significantly between M1 
and M2, when was followed the FODMAP restrictive period (M1 = 
24.4 ± 12 g/day vs. M2 = 2.63 ± 5.4 g/day; p < 0.01). However 
there was no significant change in FODMAP intake between M2 
and M3, after reintroduction of FODMAPs (M2-M3 = 3.5 g/day; 
p > 0.05). The amounts of FODMAPs consumed by participants 
at M2, compared with those calculated in assigned dietary plans 
(DP), did not differ significantly (M2 = 2.63 ± 5.4 vs. DP = 0.96 
± 1.14 g/day; p = 0.836) (Table IV). Reported compliance in 
following the assigned diet plans was 86%. 
Mean daily energy need was 1,548 ± 121 kcal based on a 
normocaloric diet for adjusted weight. Introduction of a normoca-
loric-LFD (1,552 ± 119) to participants resulted in significant (p 
< 0.01) reduction of caloric intake between M1 and M2 (M1 = 
1,958 ± 404 kcal/day vs. M2 = 1,625 ± 304 kcal/day, respec-
tively). In this group of patients, there were no significant differ-
ences in micronutrient intake as calcium (Ca), magnesium (Mg) 
and vitamin D (Vit D) between M1, M2 and M3; although the 
intakes were always lower according the DRI in all assessments 
[M1 doses: Ca = 703 mg (daily intake recommendation –DRI = 
1000 mg), Mg = 249 (DRI = 400 mg), and Vit D = 2,16 ug (DRI = 
15 ug)]. About macronutrients, only was found significant changes 
in the glycosides consume, between M1 and M2 (233.7 g vs. 180 
g; p < 0, 01), and of the lipids, between M1 and M3 (79.4 g vs. 
57.8; p < 0, 01). Fiber and protein intake was not affected by 
changes in the diets (Table IV). 
SYMPTOMS 
According to the IBS-SSS classification, this cohort presented 
only 2/38 (4%) of the participants with a score below 75 (with-
out disease), and 33/38 (87%) classified as moderate to severe 
disease (score over 175); 25/36 of them (70%) presenting the 
sub-type constipated (IBS-C) (Table V). After introduction of LFDs, 
there were significant reductions in GI symptoms. The average 
improvement in IBS-SSS score was 132 ± 117, representing a 
significant 50% reduction after 4 weeks of LFDs (M1 = 275.3 
vs. M2 = 137.4; p < 0.01) (Table III). The symptoms of Abdomi-
nal Pain and Distension also showed significant reductions after 
introduction of LFDs, between M1 and M2 (M1 = 5.0 vs. M2 = 
2.4 and M1 = 6.9 vs. M2 = 2.8; p < 0.01; in pain and disten-
sion, respectively) (Table III). But, these declines were no longer 
significant after reintroduction of FODMAPS. There was also a 
significant reduction in constipation with LFDs during M1 and M2, 
Table I. Participant body composition  
(n = 38)
Weight (kg)* 69 ± 12
BMI (kg/m2)*
BMI classes**
 Normal weight
 Overweight
 Obesity
27.4 ± 4.6
29%
37%
34%
Waist circumference (cm) * 84 ± 9
% Fat mass * 39.4 ± 7
% Fat free mass * 25.5 ± 3
Energetic needs* 1548 ± 121
*Value expressed as MEAN ± SD; **Expressed as a percentage value. 
Table II. Comparison of repeated assessment of nutritional status between different 
assessment periods (M1, M2 and M3) of the trial (n = 31) 
Parameter M 1 M2 M3 p-value (M1-M2) (M2-M3)
Weight, kg 68.36 67.08 67.1 p < 0.01b * ns
BMI, kg/m2 27.2 26.8 26.8 p < 0.01b * ns
WC (cm) 83.9 81.4 81.4 p < 0.01b * ns
Fat mass, % 39.4 38.8 38.9 0.20b ns ns
Fat free mass, % 25.5 25.7 25.9 0.33b ns ns
FODMAP: low fermentable oligo-, di-, mono-saccharides and polyols); BMI: body mass index; WC: waist circumference; *Significant. ap-value of Friedman test. bp-value 
of analysis of variance (ANOVA).
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and a non-significant increasing after reintroduction of FODMAP, 
as assessed at M3 (M1 = 5.7, M2 = 3.3, M3 = 3.8; p < 0.05) 
(Table III).
There were significant declines (patient improvement) in all 
individual FM symptoms between M1 and M2, especially with 
scores on somatic pain (VAS) (M1 = 6.6, M2 = 4.9; p < 0.01) and 
muscle tension (M1 = 6.1, M2 = 4.9; p < 0.01) in accordance 
with the reduction in severity of FM (M1 = 22; M2 = 17; p < 
0.01). No significant differences were noted after reintroduction 
of FODMAPs. The distress score throughout the trial and was not 
aggravated by reintroduction of FODMAPs (M1 = 1.8; M2 = 1.6; 
M3 = 1.5) (Table III).
It was found notable, positive correlations between improve-
ments of somatic pain (declined VAS scores) with a number of 
Table III. Repeated assessments of symptoms scores (n = 31) 
Parameter M1 M2 M3 P value M1-M2 M2-M3
 FM Severity Score 21.8 16.9 17.0 p < 0.01a * ns
IBS Severity Score 275.3 137.4 158.1 p < 0.01b * ns
Distress Score 1.8 1.6 1.5 p < 0.01b * ns
VAS generalize pain 6.6 4.9 5.4 0.000a * ns
Muscle tension 6.1 4.6 4.7 0.002a * ns
Asthenia 7.3 5.8 5.6 0.024b ** ns
Depression 5.1 4.2 4.0 0.043a ** ns
Sleep quality 6.6 5.1 5.0 0.017b ** ns
Memory 6.9 5.0 5.5 0.001a * ns
Headache 4.9 3.8 4.0 0.046a ** ns
Abdominal pain 5.0 2.4 3.0 0.000b * ns
Constipation 5.7 3.3 3.8 0.012b ** ns
Diarrhoea 2 0.8 1.5 0.019b ** ns
Bloating 6.9 2.8 3.8 0.000b * ns
ap-value ANOVA. bp-value of Friedman test. *Statistically significant differences between M1 and M2 (p < 0.01). **Statistically significant differences between M1 and 
M2 (p < 0.05).
Table IV. Comparisons of nutritional intake between different assessment periods  
(M1, M2 and M3) of the trial (n = 31) and between LFD and DP
M1 M2 M3 p-value M1-M2 M2-M3 DP M2-DP
FODMAPs, g 24.4 2.6 6.1 p < 0.01a * ns 0.96 ns
Energy, kcal 1973 1615 1566 p < 0.01b * ns 1556 ns
Glycosides, g 233.7 180.0 178.5 p < 0.01b * ns 203 ns
Protein, g 74.1 71.8 68.1 p = 0.295b ns ns 70.7 ns
Lipids, g 79.4 65.2 57.8 p < 0.01a¥ ns ns 53.9 ns
Fiber, g 22.7 21.1 20.7 p = 0.29b ns ns 22.3 ns
Calcium ,mg 703 717 708 p = 0.90a ns ns 817 ns
Magnesium, mg 249 223 242 p = 0.30a ns ns 252 ns
Vitamin D, ug 2.16 3.06 2.71 p = 0.96a ns ns 2.5 ns
DP: dietary plan; LFD: low FODMAP diet. *Statistically significant difference between M1 and M2 (p < 0.01). ¥Statistically significant difference between M1 and M3 
ONLY (p < 0.01). ap-value of Friedman test. bp-value of analysis of variance (ANOVA).
Table V. Characterization of 
gastrointestinal symptoms of FM among 
participants prior to initiation of the trial 
Score IBS-SSSa
 No disease/remission
 Mild disease
 Moderate disease
 Serious illness
275.3 ± 101
4% (2/38)
9% (3/38)
50% (19/38)
37% (14/38)
0 a 500
< 75
75-175
175-300
> 300
IBS-C
IBS-M
IBS-D
70% (25/36)
22% (8/36)
8% (3/36)
aExpressed as mean ± SD. IBS-SSS: Irritable Bowel Syndrome symptom 
severity scale; IBS with constipation (IBS-C), with diarrhoea (IBS-D) and mist 
(IBS-M). 
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GI symptoms, including abdominal pain (rs = 0.443; p < 0.01), 
abdominal distension (rs = 0.386; p < 0.05) and with the 
improvement of IBS-SSS score (rs = 0.406; p < 0.01). Of par-
ticular note was “rate of satisfaction with improvement in symp-
toms” being strongly correlated (r = 0.650; p <0.01) with “diet 
compliance rate”, suggesting patients were conscious of LFDs 
lowering severity of symptoms. In concordance, was reported 77% 
of satisfaction with the diet in general and was observed 85% of 
compliance to diet plans. 
DISCUSSION
This was the first clinical trial wherein a LFD intervention was 
experimented as a potential therapeutic approach for FM. The 
results of this pilot intervention with LFD, suggest beneficial influ-
ence on the outcome of somatic and visceral symptoms of FM 
(27). The study could prove that, the dietary plan implemented 
restricted in FODMAPs, was nutritionally balanced and provided a 
healthy diet, with benefits on weight status, at least for the period 
of the duration of the trial (4-8 week). Was found a very significa-
tive compliance to the assigned diets, comparing the participants 
FODMAPs intake with DP content.
There are some concerns regarding safety and nutritional bal-
ance of LFDs (28). LFDs prescribed in our study were helpful in 
providing a balanced intake of energy, macro- and micronutrients.
Our cohort exhibited nutritional status profiles similar to previous 
studies describing FM body composition (6) with a high preva-
lence of overweightness and high fat mass (29,30). The majority 
of research already done on FM, presents the weight loss as being 
crucial on alleviating its impact (7,31). We found a nutritional bene-
fit provided by the prescribed LFDs, resulting in weight-loss without 
significant decrease in essential nutrient intake (protein, fiber, cal-
cium, magnesium, vitamin D. The nutritional counselling promoted 
a tendency to improve the intake of important nutrients as calcium 
and vitamin D without, however, to be sufficient to achieve the 
recommended levels for the needs of these patients. The micro-
nutrient intake was generally low in all assessed moments, which 
agrees with the data of publications describing the same pattern 
of nutritional deficiencies in FM (32,33). 
The results of this trial have notable commonalities with other 
study’s, where was implemented a LFD therapy for IBS treatment 
(16,18,28). LFD was found to alleviate symptoms of IBS in all 
published studies, providing an improvement of 75% in IBS cas-
es. In IBS, LFD was found to be especially effective in relieving 
abdominal pain and distension, but was less effective in mitigat-
ing constipation (16,28). Also, we found this response among 
our cohort of FM patients, with alleviation of GI symptoms by 
LFD therapy and the most prominent response in abdominal pain 
and distension. These results reflect those published by Perez 
et al. where 31 IBS patients were treated with LFD for 21 days 
(34). Additional comparison between ours and Perez et al. results, 
shows reductions in VAS abdominal pain scores (6 to 2.8 vs. 5 to 
2.4, respectively) and VAS distension scores (7.0 to 4.2 vs. 6.9 
to 2.2, respectively). 
The results of the intervention in the subgroup of FM constipated 
patients, are consistent with the Rao et al. opinion (28), about IBS 
patients treated with LFD. The study also found reduction in the 
global IBS score in IBS-C sub-type, when treatment of LFD was 
implemented. Thus, LFD can to be a potential therapy in FM patients 
suffering from constipation but, such therapy, needs to be accom-
panied by educating patients to strictly adhere to recommended 
levels of dietary fiber and water intake. Other studies report a large 
predominance of constipation (IBS-C sub-type 90%) in patients with 
FM (19,34). Our trial showed a 70% prevalence of constipation 
(25/36, IBS-C), 8% with diarrhoea (3/36, IBS-D) and 22% with 
mixed symptoms of diarrhoea and constipation (8/36, IBS-M). The 
prevalence of IBS-C in FM sufferers appears to be higher than in 
patients with only IBS, in general, where it is reported to be about 
50% of cases (35). Another study of LFD therapy for IBS showed this 
same profile: 64.5% IBS-C, 22.6% IBS-D and 12.9% IBS-M (32). 
Authors (28) discuss the possibility that the reduced fiber intake of 
the LFD may contribute to constipation aggravation. Regarding the 
data from our study, we found that fiber intake was not significantly 
different throughout the trial and fiber consumption was always 
sufficient in relation to the daily needs in this trial. Based on these 
observations, we concluded fiber content did not contribute to any 
changes in FM symptoms in our study.
It should be noted that the reduction of prebiotic fiber, result-
ed from the fructo-oligosaccharide LFD restriction, is described 
as a possible risk factor to colon health and can contribute to 
constipation and colorectal cancer (28,36). However, these risks 
appear to be contradictory to the evident improvement of IBS 
symptomatology treated with LFD, as described by authors (16) 
and confirmed in our study with FM patients suffering from con-
comitant IBS. This contradiction has been described by authors 
as the “paradox of the LFD” (3). Furthermore, the eventual risk of 
lowering prebiotic fiber content could be avoided by concomitant 
inclusion of probiotics in LFD therapy. This hypothesis has already 
been proposed (16) but has yet to undergo study. 
The more remarkable results of our study were the alleviation of FM 
symptoms as somatic pain, muscle tension and impact in the daily 
life of FM, after treatment with LFDs. Moreover, gradual improvement 
of distress score, throughout our study, was an added contribution of 
LFD therapy to symptomatic improvements. The positive correlation 
between reductions in somatic pain and GI disorders, in our study, 
is also notable. More extensive research is needed to discern the 
interconnection between these symptoms in FM patients.
There are many other aspects of LFD therapy open to future 
research. One is determining what role, if any, LFD-therapy plays 
in the neuro-enteric axis of FM patients. Also, cost/benefit analysis 
of implementing LFD-therapy for treating FM needs to be investi-
gated, similar to what has already occurred for IBS. 
CONCLUSION
FM is a disease that requires a treatment with multidisciplinary 
approach and nutrition approach has a strong potential. Our study 
is the first clinical trial that evaluate LFD-intervention integrated 
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into FM patient treatment. The diet therapy, LFD, prescribed in 
this study was shown to have positive impact on FM symptoms, 
especially with painful hypersensitivity, a mechanism commonly 
mediating symptoms of FM and IBS. Also, LFD contributed to 
weight loss in the cohort studied, an advantage in FM sufferers 
with a high prevalence of overweightness. Moreover, LFD demon-
strated to be a balance diet without nutritional risk described in 
addition to symptomatic improvement of FM. 
Overall, this pilot study shows that a LFD could be one option 
to use as a potential dietary approach to FM treatment but these 
limited results imply cautious optimism towards use of LFD ther-
apy for FM and, at a minimum indicate, more extensive studies 
must be conducted to verify its efficacy and safety.
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